HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

559.164

+3.7570.68%

Number of Gainers:17

Number of Losers:13

Number of Flat:4

PE:- -

High:565.023

Open:555.407

Low:554.824

Close:555.407

Volume:70.83M

Turnover:1.19B

Market Cap:349.35B

Float Cap:312.56B

Loading ...

BRIEF-Immunotech Biopharm Subscribes To Structured Deposit Product With Investment Value Of RMB50 MLN

IMMUNOTECH-B Allocates 50 Million Yuan to Structured Deposit from Shanghai Pudong Development Bank

Immunotech Biopharm - Subscribed to Structured Deposit Product With Investment Value of RMB50 Mln

THOMSON REUTERS

Revised title

AH Share Premium Rankings as of February 25

Antengene-B Shares Surge Over 6% Following Clinical Collaboration Agreement with Junshi Bio

CStone Pharmaceuticals-B Sees Further Gains Exceeding 6%, Surpassing 25% Monthly Increase

Waterdrop's Yifan Pharma Deploys China's First AI-Powered Patient Matching Patent for Clinical Trials

SINOMAB BIO-B Shares Climb Over 5% in Morning Session; Phase II Trial for SM17 in Atopic Dermatitis Expected to Start in Q2

Frontier Biotechnologies, a Sub-¥8 Billion Market Cap Biopharma, Plummets to Become A-Shares' Biggest Loser

MicroPort CardioFlow's Share Consolidation Takes Effect

MT Newswires Live

Antengene Clinches Clinical Collaboration With Junshi Biosciences on ATG-037 and JS207 Combo

Antengene Announces Clinical Collaboration With Junshi Biosciences to Explore the Synergistic Potential of Atg-037 (Oral Cd73 Inhibitor) in Combination With Js207 (Pd-1/Vegf Bsab)

THOMSON REUTERS

Pharmaceutical Licensing Deals Surge as Domestic R&D Capabilities Strengthen

SINOMAB BIO-B Receives NMPA Clearance for SM17 IBD Clinical Trial Application

China NMPA approves SinoMab SM17 IND for inflammatory bowel disease

Zai Lab Ltd expected to post a loss of 6 cents a share - Earnings Preview

Zai Lab Ltd. Files List of Directors With HKEX

MP CARDIOFLOW-B (02160): Share Consolidation Takes Effect

EVEREST MED Shareholders Pass Key Commercialization Agreements at Special Meeting

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BK1574/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":559.164,"timestamp":1772006913275,"preClose":555.40704,"halted":0,"volume":70825490,"delay":0,"changeRate":0.006764,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Not Yet Opened","change":3.756958,"latestTime":"02-25 16:00:00","open":555.40704,"high":565.0227,"low":554.8237,"amount":1186294553,"amplitude":0.018363,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1772069400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1771983000000,1771992000000],[1771995600000,1772006400000]],"pbRate":4.798621,"peRate":-38.709778,"turnoverRate":0.002675,"increases":15,"decrements":15,"flats":2,"marketCap":349351766656,"floatMarketCap":312559889456},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":565.0227,"amplitude":0.018363,"preClose":555.40704,"low":554.8237,"pbRate":"4.798621","latestPrice":559.164,"volume":70825490,"delay":0,"open":555.40704,"prevYearClose":556.26263,"prevWeekClose":571.129,"prevMonthClose":555.241,"prevQuarterClose":556.263,"fiveDayClose":557.414,"twentyDayClose":584.996,"sixtyDayClose":603.244,"secType":"PLATE","market":"HK","turnoverRate":0.002675,"peRate":-38.709778,"marketCap":349351766656,"floatMarketCap":312559889456,"timestamp":1772006913275,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":17,"down":13,"flat":4},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2614365990","title":"BRIEF-Immunotech Biopharm Subscribes To Structured Deposit Product With Investment Value Of RMB50 MLN","url":"https://stock-news.laohu8.com/highlight/detail?id=2614365990","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614365990?lang=en_us&edition=fundamental","pubTime":"2026-02-25 23:06","pubTimestamp":1772031975,"startTime":"0","endTime":"0","summary":"BRIEF-Immunotech Biopharm Subscribes To Structured Deposit Product With Investment Value Of RMB50 MLNFeb 25  - Immunotech Biopharm Ltd 6978.HK:SUBSCRIBED TO STRUCTURED DEPOSIT PRODUCT WITH INVESTMENT VALUE OF RMB50 MILLIONFurther company coverage: 6978.HK ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL1NE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","06978","BK1574"],"gpt_icon":0},{"id":"1107726448","title":"IMMUNOTECH-B Allocates 50 Million Yuan to Structured Deposit from Shanghai Pudong Development Bank","url":"https://stock-news.laohu8.com/highlight/detail?id=1107726448","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107726448?lang=en_us&edition=fundamental","pubTime":"2026-02-25 23:04","pubTimestamp":1772031856,"startTime":"0","endTime":"0","summary":"IMMUNOTECH-B (06978) has announced the acquisition of a structured deposit product from Shanghai Pudong Development Bank Co.,Ltd. on February 25, 2026, with a total investment value of RMB 50 million.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","06978","LU0469268626.HKD","LU1808992512.USD","LU1934453819.USD","BK0086","BK0201","BK0188","BK0015","BK1161","BK0187","BK0012","SGXZ49509284.SGD","600000","LU1979443071.USD","BK0183","SGXZ81163826.USD","BK1574","BK0278"],"gpt_icon":0},{"id":"2614003505","title":"Immunotech Biopharm -  Subscribed to Structured Deposit Product With Investment Value of RMB50 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2614003505","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614003505?lang=en_us&edition=fundamental","pubTime":"2026-02-25 22:59","pubTimestamp":1772031583,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nFWN3ZL1NE:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06978","BK1161","BK1574"],"gpt_icon":0},{"id":"1118411444","title":"Revised title","url":"https://stock-news.laohu8.com/highlight/detail?id=1118411444","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118411444?lang=en_us&edition=fundamental","pubTime":"2026-02-25 20:14","pubTimestamp":1772021665,"startTime":"0","endTime":"0","summary":"Hanfang Pharmaceutical Submits Listing Application to Hong Kong Stock Exchange","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01477","BK1574","HEXmain","BK1191"],"gpt_icon":0},{"id":"1173309936","title":"AH Share Premium Rankings as of February 25","url":"https://stock-news.laohu8.com/highlight/detail?id=1173309936","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173309936?lang=en_us&edition=fundamental","pubTime":"2026-02-25 16:21","pubTimestamp":1772007697,"startTime":"0","endTime":"0","summary":"As of the market close on February 25, NE ELECTRIC (00042), Zhejiang Shibao Company Limited (01057), and SINOPEC SSC (01033) recorded the highest AH share premium rates, at 550.60%, 337.32%, and...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0821914370.USD","603986","LU0611395673.USD","LU1282649810.SGD","LU0348814723.USD","LU1211504680.USD","LU1993786604.SGD","IE00BZ08YS42.EUR","LU1115378108.SGD","LU2778985437.USD","LU0862451753.SGD","LU2125910500.SGD","LU0856984785.SGD","LU1048588211.SGD","LU0345780281.USD","LU1242518931.SGD","LU0488056044.USD","HK0000352382.USD","LU2226246903.HKD","LU0348735423.USD","BK1592","LU0605514214.HKD","LU0164880469.USD","LU0384037296.USD","BK1116","LU0791590937.USD","BK1501","LU0165289439.USD","LU0651946864.USD","LU0865486749.SGD","IE00BZ08YT58.USD","LU0359201885.HKD","LU0106252389.USD","LU0572944931.SGD","BK1506","BK1141","LU0502904849.HKD","LU1769817179.HKD","LU0163747925.USD","LU0328353924.USD","LU0640798160.USD","LU1146622755.USD","HK0000352291.HKD","IE00B0169L03.USD","LU0828237510.HKD","BK1544","LU1282648689.USD","BK1214","LU0543330566.HKD","LU1481107354.HKD","LU0594300179.USD","LU0181495838.USD","LU0293314216.USD","IE00BVYPNP33.GBP","002703","LU0049112450.USD","LU0049853897.USD","01057","LU0244354667.USD","LU0588545730.USD","LU1251922891.USD","LU1282649067.USD","LU0315178854.USD","LU0287142896.SGD","LU0594300419.USD","LU0164872284.USD","LU1051768304.USD","LU0823426308.USD","03145","LU1366334651.USD","PNGAY","LU2424517915.HKD","IE00B031HY20.USD","LU0052750758.USD","LU0307460666.USD","SG9999000459.SGD","IE00BGHQDM52.EUR","LU0890818403.SGD","LU1044875133.USD","LU1981816686.USD","LU0315179316.USD","SG9999002463.SGD","PAImain","BK1550","LU0651947912.USD","LU0784639295.USD","BK1543","159982","LU0345780521.USD","LU1044874839.SGD","LU0106959298.USD","LU0819123356.HKD","IE00BF5LJ272.USD","LU0456827905.SGD","LU0456846285.SGD","HK0000320264.USD","LU0531971595.HKD","LU1504937902.USD","LU1282649141.HKD","LU0455707207.USD","LU0898667661.SGD","LU0235996351.USD","LU0043850808.USD","BK1198","LU1282651121.HKD","LU0918141705.HKD","LU1820825898.SGD","LU1046422090.SGD","SG9999002828.SGD","LU0140636845.USD","IE00BMCWC346.EUR","LU1226287529.USD","BK1237","LU1688375341.USD","LU0084288322.USD","LU1807302812.USD","LU0516423091.SGD","BK1202","LU0441854154.USD","LU1515016050.SGD","LU0463099449.HKD","LU0348788117.USD","SG9999002562.SGD","600871","BK1149","BK1546","LU0348783233.USD","LU1048596156.SGD","IE00B543WZ88.USD","LU2097828805.USD","LU0737861772.HKD","IE00B5MMRT66.SGD","LU0054450605.USD","BK1515","03986","LU2153592121.USD","LU0072462343.USD","LU0228367735.SGD","BK1171","LU0516422440.USD","BK1110","BK1148","LU0326950275.SGD","BK1174","BK1610","LU0708995583.HKD","SG9999004220.SGD","LU0370786039.SGD","HK0000320223.HKD","LU0228659784.USD","LU0266512473.USD","LU1831875114.USD","LU0648948544.HKD","LU1235295612.USD","LU2242644610.SGD","IE00B29SXG58.USD","BK1551","IE0008368742.USD","LU0327786744.USD","LU0882747503.HKD","BK1564","IE00B3M56506.USD","LU0828237940.HKD","LU1224444064.USD","03750","LU1282651048.USD","BK1505","LU2543165471.USD","LU0831093199.SGD","LU0449515922.USD","LU0791591158.USD","LU0348816934.USD","LU0862451837.USD","LU0561508036.HKD","LU1051769294.HKD","LU1044876610.USD","LU1720050803.USD","LU0210527791.USD","LU0417516902.SGD","IE00BVYPNQ40.USD","BK1576","LU0630378692.HKD","LU1303224171.USD","LU0229945570.USD","LU0197773673.USD","SG9999006597.SGD","BK1523","BK1507","LU0117841782.USD","LU1961090484.USD","LU0650527681.SGD","IE00BZ08YR35.GBP","BK1240","BK1554","LU1960683339.HKD","LU2097828631.EUR","BK1105","LU0348784397.USD","LU0634319403.HKD","LU0675040207.SGD","LU0540923850.HKD","LU0878005551.USD","LU0762542818.HKD","LU0819121731.USD","LU0164939612.USD","IE00B031J352.USD","BK1229","LU0417516738.SGD","LU0211977185.USD","LU2097828714.EUR","LU0593848301.USD","BK1183","LU0117844026.USD","LU2399975544.HKD","LU0516422366.SGD","IE0034224299.USD","LU1675838814.USD","LU0620787316.HKD","IE0008369823.USD","SG9999001903.USD","LU0197773160.USD","LU2293587155.HKD","HK0000306701.USD","LU1880383366.USD","LU0417516571.SGD","LU0039217434.USD","IE0031814852.USD","HPAD.SI","LU0314109678.HKD","LU0886674414.USD","HK0000306685.HKD","LU3063872942.SGD","LU0149534421.HKD","IE00BPRC5H50.USD","LU2039709279.SGD","LU0359201612.USD","BK1594","LU0880133367.SGD","LU1366334578.USD","LU0348825331.USD","LU1242518857.USD","LU2348773727.SGD","SG9999014674.SGD","LU0348783662.USD","LU2152927971.USD","LU0516422952.EUR","LU1152091754.HKD","BK1163","600036","LU1880383440.USD","82318","LU0359202008.SGD","01033","LU0516423174.USD","LU0082770016.USD","IE0003895053.USD","LU0456854461.SGD","LU0266512127.USD","LU1769817096.USD","LU0823426480.USD","LU0501845795.SGD","LU1808992512.USD","399300","LU0588545490.SGD","LU0737861699.HKD","LU0011963245.USD","LU0979878070.USD","LU2097828474.EUR","03143","LU1008478684.HKD","LU1224709979.USD","LU0061477393.USD","LU0469268626.HKD","LU2476274308.USD","LU2476274720.SGD","BK1574","LU0589944569.HKD","LU0588546209.SGD","LU0878004406.USD","LU2045819591.USD","LU0320764599.SGD","LU1719994722.HKD","LU2348774022.SGD","LU0607220059.USD","LU0871576103.HKD","LU0254981946.USD","LU1023057109.AUD","LU1188198961.HKD","BK1258","LU0173614495.USD","LU0196878994.USD","LU1770034418.SGD","601318","LU0762540952.USD","LU0762541174.USD","LU1813983027.USD","LU0048580855.USD","BK1583","LU0588545904.SGD","LU0067412154.USD","IE00BYV24P56.USD","BK1144","BK1223","LU0431992006.USD","00042","LU0329678170.USD","LU0918141887.USD","LU0096374516.USD","LU2097828557.USD","BK1184","LU1328277881.USD","LU0868486357.SGD","LU0082770016.SGD","BK1514","BK1535","LU1152091168.USD","BK1231","BK1124","LU0329678337.USD","LU0797268264.HKD","BK1521","CIHKY","LU0348827113.USD","BK1161","LU1105468828.SGD","LU1655091459.SGD","LU2153591404.USD","LU0348805143.USD","BK1560","LU0164865239.USD","LU0231483743.USD","LU0051755006.USD","LU0831103253.SGD","BK1562","03968","BK1191","300750","BK1147","LU1642822792.SGD","LU0149721374.USD","LU0630378429.USD","LU0072913022.USD","LU1794554557.SGD","BK1522"],"gpt_icon":1},{"id":"1196731985","title":"Antengene-B Shares Surge Over 6% Following Clinical Collaboration Agreement with Junshi Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=1196731985","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1196731985?lang=en_us&edition=fundamental","pubTime":"2026-02-25 14:20","pubTimestamp":1772000437,"startTime":"0","endTime":"0","summary":"Antengene-B (06996) rose more than 6%, with the stock up 6.4% to HK$3.66 at the time of writing, recording a turnover of HK$13.326 million. The company announced this morning that it has entered into...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1515","688180","BK4585","BK1574","VT","BK4588","VXUS","01877","BK0239","06996","BK1583","BK1191"],"gpt_icon":0},{"id":"1109278324","title":"CStone Pharmaceuticals-B Sees Further Gains Exceeding 6%, Surpassing 25% Monthly Increase","url":"https://stock-news.laohu8.com/highlight/detail?id=1109278324","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109278324?lang=en_us&edition=fundamental","pubTime":"2026-02-25 14:10","pubTimestamp":1771999823,"startTime":"0","endTime":"0","summary":"CStone Pharmaceuticals-B (02616) rose more than 6% again, bringing its cumulative increase for the month to over 25%. As of the time of writing, the stock was up 5.03%, trading at HK$6.68 with a...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","02616","III","VXUS","BK1574","BK4585","BK1161","VT","BK4134"],"gpt_icon":0},{"id":"1191333349","title":"Waterdrop's Yifan Pharma Deploys China's First AI-Powered Patient Matching Patent for Clinical Trials","url":"https://stock-news.laohu8.com/highlight/detail?id=1191333349","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191333349?lang=en_us&edition=fundamental","pubTime":"2026-02-25 13:14","pubTimestamp":1771996477,"startTime":"0","endTime":"0","summary":"Beijing Yifan Fengshun Pharmaceutical Technology Co., Ltd., a subsidiary of Waterdrop Inc., has recently been granted a national invention patent for its independently developed \"Intelligent Patient...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK4539","BK1574","BK1161","09939","BK4173","BK4509","159938","WDH"],"gpt_icon":0},{"id":"1123901653","title":"SINOMAB BIO-B Shares Climb Over 5% in Morning Session; Phase II Trial for SM17 in Atopic Dermatitis Expected to Start in Q2","url":"https://stock-news.laohu8.com/highlight/detail?id=1123901653","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123901653?lang=en_us&edition=fundamental","pubTime":"2026-02-25 11:58","pubTimestamp":1771991919,"startTime":"0","endTime":"0","summary":"SINOMAB BIO-B (03681) rose more than 5% in morning trading. At the time of writing, the stock was up 4.48% to HK$2.1, with a turnover of HK$9.53 million. The company announced that on February 24,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681","BK4588","BK1574","AD","VT","BK4132","BK1161","VXUS","BK4585"],"gpt_icon":0},{"id":"1198191320","title":"Frontier Biotechnologies, a Sub-¥8 Billion Market Cap Biopharma, Plummets to Become A-Shares' Biggest Loser","url":"https://stock-news.laohu8.com/highlight/detail?id=1198191320","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198191320?lang=en_us&edition=fundamental","pubTime":"2026-02-25 11:40","pubTimestamp":1771990845,"startTime":"0","endTime":"0","summary":"The company had just concluded an authorization deal valued at over $1 billion. On February 25th, the stock price of STAR Market-listed biopharmaceutical firm Frontier Biotechnologies Inc....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06978","BK1574","159982","688221","BK0239","159992","399300","BK1161"],"gpt_icon":0},{"id":"2614775218","title":"MicroPort CardioFlow's Share Consolidation Takes Effect","url":"https://stock-news.laohu8.com/highlight/detail?id=2614775218","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614775218?lang=en_us&edition=fundamental","pubTime":"2026-02-25 11:01","pubTimestamp":1771988501,"startTime":"0","endTime":"0","summary":"MicroPort CardioFlow Medtech  said its 5-for-1 share consolidation became effective on Tuesday after all conditions were fulfilled, according to a same-day Hong Kong bourse filing.Under the consolidation, every five existing shares of $0.000005 each were consolidated into one share of $0.000025 each.Based on 6.37 billion shares in issue before the exercise, the number of issued shares was reduced to about 1.27 billion following the consolidation.The board lot size remains unchanged at 1,000 shares.The company had said the consolidation is intended to increase the trading price per share and raise the board lot value above HK$2,000 in line with trading requirements.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1100","02160","BK1583","BK1574"],"gpt_icon":0},{"id":"2614722910","title":"Antengene Clinches Clinical Collaboration With Junshi Biosciences on ATG-037 and JS207 Combo","url":"https://stock-news.laohu8.com/highlight/detail?id=2614722910","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614722910?lang=en_us&edition=fundamental","pubTime":"2026-02-25 08:30","pubTimestamp":1771979415,"startTime":"0","endTime":"0","summary":"Antengene Corporation Ltd. has entered into a clinical collaboration agreement with Shanghai Junshi Biosciences to jointly evaluate Antengene’s oral CD73 inhibitor ATG-037 in combination with Junshi’s PD-1/VEGF bispecific antibody JS207 in solid tumor patients in Mainland China. The partners aim to assess potential synergy across multiple tumor types and identify clinical signals that could improve outcomes by targeting immune checkpoints, angiogenesis and adenosine-mediated immunosuppression.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nNDL3CMYrg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1583","BK1574","BK0239","688180","06996"],"gpt_icon":0},{"id":"2614914722","title":"Antengene Announces Clinical Collaboration With Junshi Biosciences to Explore the Synergistic Potential of Atg-037 (Oral Cd73 Inhibitor) in Combination With Js207 (Pd-1/Vegf Bsab)","url":"https://stock-news.laohu8.com/highlight/detail?id=2614914722","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2614914722?lang=en_us&edition=fundamental","pubTime":"2026-02-25 08:30","pubTimestamp":1771979400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260225:nTUA2RVQFQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1191","BK1574","BK1583","06996"],"gpt_icon":0},{"id":"1121856522","title":"Pharmaceutical Licensing Deals Surge as Domestic R&D Capabilities Strengthen","url":"https://stock-news.laohu8.com/highlight/detail?id=1121856522","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121856522?lang=en_us&edition=fundamental","pubTime":"2026-02-25 07:13","pubTimestamp":1771974813,"startTime":"0","endTime":"0","summary":"The pharmaceutical sector is experiencing a surge in business development activity following the Lunar New Year holiday. On February 24, the first trading day after the break, Frontier...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09939","159938","BK1161","BK1515","BK1574"],"gpt_icon":0},{"id":"1105876866","title":"SINOMAB BIO-B Receives NMPA Clearance for SM17 IBD Clinical Trial Application","url":"https://stock-news.laohu8.com/highlight/detail?id=1105876866","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105876866?lang=en_us&edition=fundamental","pubTime":"2026-02-24 22:10","pubTimestamp":1771942248,"startTime":"0","endTime":"0","summary":"SINOMAB BIO-B (03681) announced that on February 24, 2026, the Investigational New Drug (IND) application for its first-in-class (FIC) therapeutic product SM17, intended for the treatment of patients...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","03681","BK1161","IBD","BK1574"],"gpt_icon":0},{"id":"2613712244","title":"China NMPA approves SinoMab SM17 IND for inflammatory bowel disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2613712244","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613712244?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:58","pubTimestamp":1771941538,"startTime":"0","endTime":"0","summary":"SinoMab BioScience Ltd. said China’s National Medical Products Administration has approved its Investigational New Drug  application for SM17 to treat inflammatory bowel disease, including Crohn’s disease and ulcerative colitis. The company said it has completed follow-up visits for a Phase I bridging study in healthy volunteers evaluating subcutaneous administration of SM17 and plans to use the data to support further clinical development, including preparation for Phase II studies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SinoMab BioScience Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 24, 2026, and is solely r","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL1R4pQR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03681","BK1574","BK1161"],"gpt_icon":0},{"id":"2613714764","title":"Zai Lab Ltd  expected to post a loss of 6 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2613714764","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613714764?lang=en_us&edition=fundamental","pubTime":"2026-02-24 21:32","pubTimestamp":1771939927,"startTime":"0","endTime":"0","summary":"Zai Lab Ltd <9688.HK> expected to post a loss of6cents a share - Earnings Preview Zai Lab Ltd 9688.HK  is expected to  show a rise in quarterly revenue when it reports  results on February 26 for the ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nL8N3ZK1FY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK1574","09688","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"2613719674","title":"Zai Lab Ltd. Files List of Directors With HKEX","url":"https://stock-news.laohu8.com/highlight/detail?id=2613719674","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2613719674?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:39","pubTimestamp":1771936772,"startTime":"0","endTime":"0","summary":"Zai Lab Limited filed an updated list of directors and their roles and functions with HKEX. Dr. Samantha Du serves as Chairperson and Chief Executive Officer, and is a member of the Research and Development Committee and the Commercial Committee. Independent directors are Dr. John Diekman, the Lead Independent Director and a member of the Audit Committee, Compensation Committee and Nominating and Corporate Governance Committee; Dr. Richard Gaynor, a member of the Compensation Committee and Chairperson of the Research and Development Committee; Ms. Nisa Leung, a member of the Nominating and Corporate Governance Committee; Mr. William Lis, a member of the Nominating and Corporate Governance Committee; Mr. Scott W. Morrison, Chairperson of the Audit Committee; Mr. Leon O. Moulder, Jr., Chairperson of the Nominating and Corporate Governance Committee and a member of the Commercial Committee; Mr. Michel Vounatsos, a member of the Research and Development Committee and Chairperson of the Com","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260224:nNDL1H78yW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1588","BK1574","09688","BK1161","LU2488822045.USD"],"gpt_icon":0},{"id":"1151556957","title":"MP CARDIOFLOW-B (02160): Share Consolidation Takes Effect","url":"https://stock-news.laohu8.com/highlight/detail?id=1151556957","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151556957?lang=en_us&edition=fundamental","pubTime":"2026-02-24 20:34","pubTimestamp":1771936453,"startTime":"0","endTime":"0","summary":"MP CARDIOFLOW-B (02160) has announced that all conditions for the share consolidation were satisfied on February 24, 2026. The share consolidation became effective starting February 24, 2026.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1239","BK1100","BK1574","02918","BK1583","02160","BK1225"],"gpt_icon":0},{"id":"1121333319","title":"EVEREST MED Shareholders Pass Key Commercialization Agreements at Special Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1121333319","media":"Stock News","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121333319?lang=en_us&edition=fundamental","pubTime":"2026-02-24 18:08","pubTimestamp":1771927696,"startTime":"0","endTime":"0","summary":"EVEREST MED (01952) announced the successful conclusion of its Special General Meeting held virtually on February 24, 2026, where all proposed resolutions were formally approved by shareholders....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01952","BK1583"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":120,"code":"91000000","status":"200"}]}}